History of Nycomed Amersham Imaging:
2001 The transfer of the imaging products onto those ones new set up Amersham Health AG.
2000 The sale of the diagnostic fields at Axis-Shield. The NycoCard marketed products through Nycomed AG in the Switzerland still.
1999 The solution of the fusion and incorporation of imaging as an own department.
1998 The fusion with Amersham, change of the name in Nycomed Amersham AG.
1996 The Name Hafslund is omitted, the company occurs only under the name Nycomed.
1990 The company Hafslund Nycomed is starting with imaging products.

Knee MRI, with its high soft tissue contrast is one of the main imaging tools to depict knee joint pathology. MRI allows accurate imaging of intra-articular structures such as ligaments, cartilage, menisci, bone marrow, synovium, and adjacent soft tissue.
Knee exams require a dedicated extremity coil, providing a homogenous imaging volume and high SNR to ensure best signal coverage. A complete knee MR examination includes for example sagittal and coronal T1 weighted, and proton density weighted pulse sequences +/- fat saturation, or STIR sequences. For high spatial resolution, maximal 4 mm thick slices with at least an in plane resolution of 0.75 mm and small gap are recommended. To depict the anterior cruciate ligament clearly, the sagittal plane has to be rotated 10 - 20° externally (parallel to the medial border of the femoral condyle). Retropatellar cartilage can bee seen for example in axial T2 weighted gradient echo sequences with Fatsat. However, the choice of the pulse sequences is depended of the diagnostic question, the used scanner, and preference of the operator.
Diagnostic quality in knee imaging is possible with field strengths ranging from 0.2 to 3T. With low field strengths more signal averages must be measured, resulting in increased scan times to provide equivalent quality as high field strengths.
More diagnostic information of meniscal tears and chondral defects can be obtained by direct magnetic resonance arthrography, which is done by introducing a dilute solution of gadolinium in saline (1:1000) into the joint capsule. The knee is then scanned in all three planes using T1W sequences with fat suppression. For indirect arthrography, the contrast is given i.v. and similar scans are started 20 min. after injection and exercise of the knee.
Frequent indications of MRI scans in musculoskeletal knee diseases are:
e.g., meniscal degeneration and tears, ligament injuries, osteochondral fractures, osteochondritis dissecans, avascular bone necrosis and rheumatoid arthritis.

See also Imaging of the Extremities and STIR.

On October 19, 2001, Philips Medical Systems completed an acquisition strategy through its purchase of Marconi Medical Systems.

The History of Marconi Medical Systems
2001 Royal Philips Electronics and Marconi plc announced that Philips has agreed to acquire Marconi Medical Systems for $1.1 billion.
2000 Marconi introduces Infinite Detector Technology for Mx8000 multislice CT scanner, which acquires an unprecedented 16 simultaneous slices with sub-millimeter isotropic accuracy.
1999 At RSNA, Picker International unveils the new Marconi Medical Systems name and corporate vision.
1998 Picker International acquires the Computed Tomography Division of Elscint Ltd, immediately positioning Picker at the forefront of major global CT suppliers.
1986 Picker produces the industry's first 1.0T MR imager.
1981 Picker is sold to General Electric Co. Ltd. of England (GEC). Picker merged with Cambridge Instruments, GEC Medical, and American Optical to form Picker International.
1967 The name changed from Picker X-ray to Picker Corporation. Picker acquired Dunlee.
1946 The Dunlee Corporation started in Chicago by Dunmore Dunk and Zed. J. Atlee to meet demand for quality X-ray tubes and special purpose tubes.
1915 James Picker Company formed in New York City offering sales and service of X-ray equipment, film and accessories.

See also Philips Medical Systems and MRI History.

Short name: CMC 001, central moiety: Mn2+
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract. Applications are screening of liver tumors/metastases, imaging of the biliary tract and it could be suitable for liver function studies by following the metabolism and excretion of manganese in the liver cells. Several advantages like better images, higher safety, lower costs and less inconvenience for the patient can be expected.
Animal experiments and clinical studies in humans Phase I and Phase II A, have shown excellent contrast enhancing properties with only minimal adverse effects. CMC 001 is under development by the Medicon Valley based CMC Contrast AB to receive a cost effective, safe and highly diagnostic MR contrast medium for abdominal MR imaging. Clinical studies in Phase III are started.

Short name: P792, generic name: Gadomeritol, preliminary trade name: Vistarem™, central moiety: Gd
A macromolecular Gd-DOTA derivate under development as a MRI blood pool agent with rapid clearance. Phase II of the clinical trials on P792 (Guerbet SA) will make it possible to validate the performance of this agent in the fields of angiography, myocardial perfusion and tumor characterization.